Justin Gover - GW Pharmaceuticals CEO, Director

CEO

Mr. Justin Gover is Chief Executive Officer, Director of GW Pharmaceuticals PLC. He has 17 years experience in the pharmaceutical industry. As Chief Executive Officer, he was the lead executive responsible for the running of our company operations, as well as in leading equity financings and business development activities. Prior to joining our company, Mr. Gover was Head of Corporationrationrate Affairs at Ethical Holdings plc from 1995 to 1997 where he was responsible for the company strategic corporate activities, including mergers and acquisitions, strategic investments, equity financings and investor relations since 1999.
Age 42
Tenure 25 years
Professional MarksMBA
Phone(44) 1223 235667
Webwww.gwpharm.com
Gover holds an M.B.A. from INSEAD and a BSc. from Bristol University.

GW Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (3.55) % which means that it has lost $3.55 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.92) %, meaning that it created substantial loss on money invested by shareholders. GW Pharmaceuticals' management efficiency ratios could be used to measure how well GW Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 43.64 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. GW Pharmaceuticals Plc has a current ratio of 4.48, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist GW Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, GW Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like GW Pharmaceuticals Plc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for GWPH to invest in growth at high rates of return. When we think about GW Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom. Gw Pharma operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 1161 people. GW Pharmaceuticals Plc (GWPH) is traded on NASDAQ Exchange in USA and employs 1,161 people.

Management Performance

GW Pharmaceuticals Plc Leadership Team

Elected by the shareholders, the GW Pharmaceuticals' board of directors comprises two types of representatives: GW Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GWPH. The board's role is to monitor GW Pharmaceuticals' management team and ensure that shareholders' interests are well served. GW Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GW Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
William Waldegrave, Non-Executive Independent Director
Christopher Tovey, COO, Executive Director
Thomas Lynch, Non-Executive Independent Director
Catherine Mackey, Non-Executive Independent Director
Justin Gover, CEO, Director
Geoffrey Guy, Executive Chairman of the Board
James Noble, Non-Executive Deputy Chairman of the Board, Senior Independent Director
Julian Gangolli, Executive Director
Alicia Secor, Non-Executive Independent Director
Adam George, CFO, Company Secretary, Director
Cabot Brown, Non-Executive Independent Director
Stephen Wright, Research & Development Director, Executive Director
Darren Cline, Chief Commercial Officer, U.S.

GWPH Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GW Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Other Consideration for investing in GWPH Stock

If you are still planning to invest in GW Pharmaceuticals Plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the GW Pharmaceuticals' history and understand the potential risks before investing.
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Stocks Directory
Find actively traded stocks across global markets